Aquestive Therapeutics adds Rich Daly to board of directors
Daly, former Catalyst Pharmaceuticals CEO, joins effective October 14, 2026, as the company prepares for a potential launch of its allergy drug Anaphylm.
SEC filing
Latest
4 stories
Tuesday, September 29
Thursday, September 17
Aquestive resubmits FDA application for Anaphylm epinephrine film
The company said new human factors and pharmacokinetic data address the FDA's prior Complete Response Letter for the needle-free anaphylaxis treatment.
SEC filing
Tuesday, August 11
Aquestive completes Anaphylm studies, keeps Q3 2026 NDA resubmission timeline
The company finished the human factors and pharmacokinetic studies tied to January's FDA rejection and reaffirmed plans to resubmit the epinephrine film's application in the third quarter.
SEC filing
Monday, August 10
Aquestive reports positive human factors and PK data for Anaphylm ahead of NDA resubmission
The company said study results support a planned third-quarter 2026 resubmission of its epinephrine sublingual film NDA after a January 2026 FDA rejection.
SEC filing